Pharma secy says Cabinet approval for Biopharma SHAKTI likely in 3 mos
This story was originally published at 12:56 IST on 11 June 2026
Register to read our real-time news.Informist, Thursday, Jun. 11, 2026
--Pharma Secy: Cabinet approval for Biopharma SHAKTI expected in 3 mos
By Gunjan Rajput and Shakshi Jain
NEW DELHI – The Union Cabinet is likely to approve the Biopharma SHAKTI scheme in the next three months, Secretary for the Department of Pharmaceuticals Manoj Joshi said Thursday at the Pharma Summit and Awards 2026, hosted by the Associated Chambers of Commerce and Industry of India.
The Union Budget for 2026-27 (Apr-Mar) had proposed an outlay of INR 100 billion over the next five years for Biopharma SHAKTI to position India as a global biopharma manufacturing hub. Biopharma SHAKTI expands to Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
However, the government wants the pharmaceuticals industry to utilise INR 100 billion under the Biopharma SHAKTI initiative within the next two years, Joshi had said in April at the India Pharma 2026, organised by the Federation of Indian Chambers of Commerce and industry.
Under Biopharma SHAKTI, the government will set up a biopharma-focused network, including three new National Institutes of Pharmaceutical Education and Research, while upgrading seven existing ones. The programme will also create a network of over 1,000 accredited clinical trial sites across the country.
Joshi earlier in his address said the government has started making changes to the pharmaceutical regulatory regime to keep pace with rapid advances in drug discovery and development. He listed supply chain resilience as a priority area for the government to help the industry and highlighted the need to fill a funding gap for startups in the sector. End
Edited by Akul Nishant Akhoury
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
